(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 June 2020 (25.06.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/127533 A1

(51) International Patent Classification:
C12N 15/85 (2006.01)

(21) International Application Number:
PCT/EP2019/086020

(22) International Filing Date:
18 December 2019 (18.12.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
18306740.4 19 December 2018 (19.12.2018) EP

(71) Applicants: **INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)** [FR/FR]; 101, Rue de Tolbiac, 75013 PARIS (FR). **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE** [FR/FR]; 3, rue Michel Ange, 75016 PARIS (FR). **UNIVERSITE COTE D'AZUR** [FR/FR]; 28 Avenue Valrose, 06100 Nice (FR).

(72) Inventor: **GOUZE, Elvire**; U1091, iBV, équipe E Gouze UMR Inserm U1091 - CNRS 7277 - UNS Parc Valrose - Bt SCI Nat 8è étage, 06108 NICE CEDEX 2 (FR).

(74) Agent: **BLOT, Philippe** et al.; 2, place d'Estienne d'Orves, 75441 PARIS CEDEX 09 (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: HYBRID PROMOTERS AND THEIR USES IN THERAPY, NOTABLY FOR TREATING TYPE II COLLAGENOPATHIES

(57) Abstract: The present invention relates to hybrid promoters with a specific design, comprising fragments of the hCOL2A1 promoter and fragments of the hEF1α promoter, which may be of interest in therapy, particularly in gene therapy. Notably, they may be introduced into a vector for expressing a nucleic acid sequence of interest. They may be particularly useful for treating skeletal dysplasia, such as type II collagenopathies; or articular diseases.

WO 2020/127533 A1